BPM Secures Second Thai FDA Approval! DNlite-IVD103 Granted Marketing Authorization for Kidney Transplant Prognostic Risk Assessment

Following last month's successful market authorization of the DNlite-IVD103 diagnostic test for Diabetic Kidney Disease (DKD) in Thailand, Bio Preventive Medicine Corp. (BPM) announces another major triumph today. The company has received official notification that its DNlite-IVD103 test, specifically designated for the prognostic risk assessment of renal graft failure in kidney transplant patients (Application Name: DNlite-KT uPTM-FetA ELISA Kit), has been granted In Vitro Diagnostic (IVD) marketing authorization by the Thai Food and Drug Administration (Thai FDA).